Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.

Trends in localized MIBC treatment have evolved substantially since the early 2000s, and certain patient characteristics are associated with lower odds of receiving the current standard of care. This serves as a foundation from which to judge the impact of the upcoming immunotherapy era on the treatment landscape for this disease.